

Technology Advisory Committee B Interests Register

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]

Publication Date: 20/11/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David McAllister	TAC B Committee Member	Non-Financial Professional interests	Conducting academic research using data provided by sponsors and/or their competitors via a trial data sharing platform (Vivli).	29/07/2024	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Professor Tim Somervaille	Clinical Expert	Direct- financial	<p>Professor Somervaille has provided consulting and speaking services to Novartis.</p> <p>Professor Somervaille provided consulting services for Novartis, BMS, Abbvie, Imago Biosciences, Oryzon Genomics and GSK intermittently over the last 5-10 years in view of his clinical expertise in the myeloproliferative disorders and myeloid blood cancers in general.</p>	14/08/2024	It was agreed that Professor Somervaille's declaration would not prevent him from providing expert advice to the committee.
Professor Beth Psalia	Clinical Expert	Direct- financial	Professor Psalia has been nominated by MPN Voice and has delivered presentations to their	14/08/2024	It was agreed that Professor Psalia's declaration would not

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>patient forums, both virtually and in person</p> <p>She has received payments from Novartis for speaking engagements, consultancy and an advisory board.</p>		prevent her from providing expert advice to the committee.
Andy Tattersall	Patient Expert	Indirect - financial	Mr Tattersall's nominating organisation and employer MPN Voice has received funding from Novartis.	14/08/2024	It was agreed that Mr Tattersall's declaration would not prevent him from providing expert advice to the committee.
Jonathan Mathias	Patient Expert	Indirect - Financial	Mr Mathias is the Co-Chair of my nominating organisation MPN Voice which has received funding from Novartis.	14/08/2024	It was agreed that Mr Mathias' declaration would not prevent him from providing expert advice to the committee.